Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Nov 1;8(11):14315-24.
eCollection 2015.

Roles of Cx43 and AKAP95 in ovarian cancer tissues in G1/S phase

Affiliations
Comparative Study

Roles of Cx43 and AKAP95 in ovarian cancer tissues in G1/S phase

Wenzhi Liu et al. Int J Clin Exp Pathol. .

Abstract

Objective: The purpose of this study was to investigate the expression of A-kinase anchor protein 95 (AKAP95), cell cycle protein E1 (cyclinE1) and D1 (cyclinD1), and gap junction protein connexin 43 (Cx43) in ovarian cancer tissues, the relationship between four proteins and clinicopathologic parameters, and the correlation between these proteins.

Methods: The expression of proteins in 54 cases of ovarian cancer tissues was detected by immunohistochemical method.

Results: The positive expression rates of AKAP95, cyclinD1 and cyclinE1 in ovarian cancer tissues were 72.22%, 66.67% and 79.63%, respectively, which were higher than that of ovarian pericarcinoma tissues expressing as 33.33%, 25% and 8.30% (P<0.05). The positive expression rate of Cx43 in ovarian cancer tissues was 40.74%, which was lower than that of ovarian pericarcinoma tissues expressing as 75%; respectively, and the difference was statistically significant between groups (P<0.05). The expression of cyclinD1 in ovarian cancer tissues was related to the histologic type (P<0.05) while it showed no correlation with the degree of differentiation (P>0.05). Additionally, the expression of AKAP95, Cx43 and cyclinE1 in ovarian cancer tissues showed no correlation with the degree of differentiation or the histologic type (P>0.05). Protein expressions of AKAP95, Cx43 and cyclinE1 were correlated with each other (P<0.05), and the expressions of cyclinD1, cyclinE1 and Cx43 were also correlated with each other (P<0.05). However, AKAP95 and cyclinD1 showed no correlation (P>0.05).

Conclusion: AKAP95, cyclinD1 and cyclinE1 play an important role in promoting the process of ovarian cancer formation. The tumor inhibitory effects of Cx43 protein on the pathogenesis of ovarian cancer were weakened. The expression of cyclinD1 in ovarian cancer tissues is related to the histologic type while it shows no correlation with the degree of differentiation. Additionally, the expression of AKAP95, Cx43 and cyclinE1 in ovarian cancer tissues shows no correlation with the degree of differentiation or the histologic type. AKAP95 expression is correlated with Cx43 and cyclinE1 expression; Cx43 expression is correlated with AKAP95, cyclinD1 and cyclinE1 expression; cyclinE1 expression is correlated with AKAP95, Cx43, cyclinD1 expression; cyclinD1 expression is correlated with Cx43 and cyclinE1 expression, while AKAP95 and cyclinD1 show no correlation.

Keywords: AKAP95; Cx43; correlation; cyclinD1; cyclinE1; ovarian cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Expression of AKAP95 in ovarian cancer tissues, ×400. A: AKAP95 was expressed in the nuclei of ovarian pericarcinoma tissues; B: AKAP95 was expressed weakly in the cytoplasm, and highly in some nuclei of ovarian serous adenocarcinoma tissues; C: AKAP95 was highly expressed in the nuclei of ovarian clear cell adenocarcinoma tissues; D: AKAP95 was weakly expressed in the nuclei of ovarian clear cell adenocarcinoma tissues; E: AKAP95 was highly expressed in the nuclei of ovarian endometrioid adenocarcinoma tissues; F: AKAP95 was negatively expressed in the nuclei of ovarian endometrioid adenocarcinoma tissues.
Figure 2
Figure 2
Expression of cyclinD1 in ovarian cancer tissues, ×400. A and B: CyclinD1 protein was weakly expressed in the cytoplasm and a few nuclei of ovarian serous adenocarcinomatissues; C and D: CyclinD1 protein was moderately expressed in the nucleus and cytoplasm of ovarian clear cell carcinoma tissues; E: CyclinD1 protein was highly expressed in the cytoplasm of ovarian mucinous adenocarcinoma tissues; F: CyclinD1 protein was highly expressed in the nuclei of ovarian mucinous adenocarcinoma tissues; G: CyclinD1 protein was moderately expressed in the nuclei of ovarian mucinous adenocarcinoma tissues; H: CyclinD1 protein was moderately expressed in the nuclei of ovarian endometrioid carcinoma tissues; I: CyclinD1 protein was moderately expressed in the cytoplasm of ovarian endometrial adenoid cancer tissues; J: CyclinD1 protein was negatively expressed in ovarian endometrioid adenocarcinoma tissues.
Figure 3
Figure 3
Expression of cyclinE1 in ovarian cancer tissues, ×400. A and B: CyclinE1 was highly expressed in the nuclei of ovarian serous adenocarcinoma tissues; C: CyclinE1 was negatively expressed in the nuclei of ovarian serous adenocarcinoma tissues; D: CyclinE1 was highly expressed in the nuclei of in ovarian clear cell carcinoma tissues; E: CyclinE1 was weakly expressed in the cytoplasm of ovarian clear cell carcinoma tissues; F: CyclinE1 was weakly expressed in the cytoplasm of ovarian mucinous adenocarcinoma tissues; G and H: CyclinE1 was highly expressed in the nuclei of ovarian endometrioid adenocarcinoma tissues; I: cyclinE1 was weakly expressed in the cytoplasm of ovarian endometrial adenocarcinoma tissues.
Figure 4
Figure 4
Expression of Cx43 in ovarian cancer tissues, ×400. A: Cx43 was highly expressed in the cytoplasm of ovarian serous adenocarcinoma tissues; B: Cx43 was negatively expressed in the cytoplasm of ovarian serous adenocarcinoma tissues; C: Cx43 was weakly expressed in the cytoplasm of ovarian clear cell carcinoma tissues; D and E: Cx43 was highly expressed in the cytoplasm of ovarian endometrial adenocarcinoma cancer tissues; F: Cx43 was negatively expressed in the cytoplasm of ovarian endometrial adenocarcinoma cancer tissues.

Similar articles

Cited by

References

    1. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. CyclinD as a therapeutic target in cancer. Nat Rev Cancer. 2011;11:558–572. - PubMed
    1. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, Nishimoto T, Morgan DO, Franza BR, Roberts JM. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science. 1992;257:1689–1694. - PubMed
    1. Arsenijevic T, Degraef C, Dumont JE, Roger PP, PirsonI I. G1/S Cyclins interact with regulatory subunit of PKA via A-kinase anchoring protein, AKAP95. Cell Cycle. 2006;5:1217–1222. - PubMed
    1. Arsenijevic T, Degraef C, Dumont JE, Roger PP, Pirson I. A novel Partner for D-tyPecyclins: Protein kinase A-anchoring Protein AKAP95. Biochem J. 2004;378:673–679. - PMC - PubMed
    1. Zhang YW, Nakayama K, Nakayama K, Morita I. A novel route for Connexin 43 to inhibit cell proliferation: negative regulation of S-phase kinase-associated protein (skp2) Cancer Res. 2003;63:1623–1630. - PubMed

Publication types